File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis

TitleThe use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2011
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4083 How to Cite?
AbstractBACKGROUND: Previous sorafenib studies in advanced hepatocellular carcinoma (HCC) involved predominantly patients with Child-Pugh A liver cirrhosis, leaving the routine administration of sorafenib to patients with more advanced liver cirrhosis controversial. This study aimed to explore the tolerability and survival benefits in using sorafenib in Child-Pugh B patients. METHODS: Advanced HCC patients treated with sorafenib at Queen Mary Hospital, Hong Kong were analyzed retrospectively. Patients were stratified into Child-Pugh A or Child-Pugh B liver cirrhosis. Toxicities were graded according to the NCI CTCAE version 3.0. RESULTS: One hundred and sixty-six advanced HCC patient were included with 106 had underlying Child-Pugh A and 60 Child-Pugh B patients. The age, gender, hepatitis status, disease stages and baseline laboratory parameters between the two groups were similar. The most common treatment related non-haematological grade 3/4 adverse events were hand-foot-syndrome (13.9%), diarrhea (9.7%), rash (7.3%) and malaise (3.6%). Moreover, grade 3/4 neutropenia and thrombocytopenia occurred in 3.0% and 4.9% of the patients in the cohort, respectively. Notably, Child-Pugh A and B patients experienced similar incidence of all these adverse events. Nonetheless, Child-Pugh B patients had higher baseline bilirubin level, and experienced more grade 3 or 4 bilirubinemia during treatment compared with Child-Pugh A patients (33.9% vs. 19.0%, p<0.05). More importantly, Child-Pugh B patients also developed more gastrointestinal bleeding (15% vs. 5.6%, p=0.05) and hepatic encephalopathy (10% vs. 1.9%, p<0.05). Overall, progression free survival was similar among the Child-Pugh A (3.2 months) and B (3.0) patients. However, the overall survival was longer in Child-Pugh A than B patients (6.0 vs 3.9 months, p<0.01). CONCLUSIONS: Child-Pugh A and B patients tolerate sorafenib similarly and derive similar survival benefit from the treatment. Nevertheless, Child –Pugh B patients are more susceptible to develop cirrhotic complications during sorafenib treatment, especially hyperbilirubinemia, gastrointestinal bleeding and hepatic encephalopathy.
DescriptionGeneral Poster Session - Gastrointestinal (Noncolorectal) Cancer: abstract no. 4083
Persistent Identifierhttp://hdl.handle.net/10722/137891
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorChiu, Jen_US
dc.contributor.authorTang, YFen_US
dc.contributor.authorYao, TJen_US
dc.contributor.authorWong, Aen_US
dc.contributor.authorWong, Hen_US
dc.contributor.authorLeung, Ren_US
dc.contributor.authorChan, Pen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorYau, CCen_US
dc.date.accessioned2011-08-26T14:36:29Z-
dc.date.available2011-08-26T14:36:29Z-
dc.date.issued2011en_US
dc.identifier.citationThe 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4083en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/137891-
dc.descriptionGeneral Poster Session - Gastrointestinal (Noncolorectal) Cancer: abstract no. 4083-
dc.description.abstractBACKGROUND: Previous sorafenib studies in advanced hepatocellular carcinoma (HCC) involved predominantly patients with Child-Pugh A liver cirrhosis, leaving the routine administration of sorafenib to patients with more advanced liver cirrhosis controversial. This study aimed to explore the tolerability and survival benefits in using sorafenib in Child-Pugh B patients. METHODS: Advanced HCC patients treated with sorafenib at Queen Mary Hospital, Hong Kong were analyzed retrospectively. Patients were stratified into Child-Pugh A or Child-Pugh B liver cirrhosis. Toxicities were graded according to the NCI CTCAE version 3.0. RESULTS: One hundred and sixty-six advanced HCC patient were included with 106 had underlying Child-Pugh A and 60 Child-Pugh B patients. The age, gender, hepatitis status, disease stages and baseline laboratory parameters between the two groups were similar. The most common treatment related non-haematological grade 3/4 adverse events were hand-foot-syndrome (13.9%), diarrhea (9.7%), rash (7.3%) and malaise (3.6%). Moreover, grade 3/4 neutropenia and thrombocytopenia occurred in 3.0% and 4.9% of the patients in the cohort, respectively. Notably, Child-Pugh A and B patients experienced similar incidence of all these adverse events. Nonetheless, Child-Pugh B patients had higher baseline bilirubin level, and experienced more grade 3 or 4 bilirubinemia during treatment compared with Child-Pugh A patients (33.9% vs. 19.0%, p<0.05). More importantly, Child-Pugh B patients also developed more gastrointestinal bleeding (15% vs. 5.6%, p=0.05) and hepatic encephalopathy (10% vs. 1.9%, p<0.05). Overall, progression free survival was similar among the Child-Pugh A (3.2 months) and B (3.0) patients. However, the overall survival was longer in Child-Pugh A than B patients (6.0 vs 3.9 months, p<0.01). CONCLUSIONS: Child-Pugh A and B patients tolerate sorafenib similarly and derive similar survival benefit from the treatment. Nevertheless, Child –Pugh B patients are more susceptible to develop cirrhotic complications during sorafenib treatment, especially hyperbilirubinemia, gastrointestinal bleeding and hepatic encephalopathy.-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleThe use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosisen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailYau, CC: tyaucc@hku.hken_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityYau, CC=rp01466en_US
dc.identifier.hkuros189734en_US
dc.identifier.volume29en_US
dc.identifier.issue15 suppl.en_US
dc.description.otherThe 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4083-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats